Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company focused on the development of prescription therapeutics for the treatment of debilitating skin diseases with a focus on its main asset for the treatment of hyperhidrosis. Co.'s investigational product candidate, sofpironium bromide, is a chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Co. is developing sofpironium bromide in the U.S. for the treatment of primary axillary hyperhidrosis. The FRTX stock yearly return is shown above.
The yearly return on the FRTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|